ERBB2 and breast cancer: Baseline SUVmax significantly correlated with tumour characteristics (Figure 2), including BC subtype (p < 0.001), HER2 expression (p < 0.001), tumour grading (p < 0.001), and Ki-67 index (p < 0.001).